PMID- 23377987
OWN - NLM
STAT- MEDLINE
DCOM- 20130725
LR  - 20231213
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 30
IP  - 1
DP  - 2013 Mar
TI  - Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and 
      prognosis in patients with stage III colorectal cancer.
PG  - 482
LID - 10.1007/s12032-013-0482-2 [doi]
AB  - Human leukocyte antigen (HLA)-E can contribute to the escape of cancer cells from 
      host immune mechanisms. However, it is unknown whether HLA-E gene polymorphisms 
      might play a role in cancer immune escape. This study aimed to evaluate the 
      correlation between HLA-E gene polymorphisms and HLA-E expression in tumor tissue 
      and determine the effects on clinical outcome of patients with stage III 
      colorectal cancer. Two hundred thirty patients with stage III colorectal cancer 
      were enrolled. HLA-E expression was detected in patient-derived tumor tissues 
      with immunohistochemistry. HLA-E gene alleles in tumor tissues were detected with 
      the polymerase chain reaction-sequence-specific primer method. In colorectal 
      cancer tissue and in the normal tissue adjacent to the tumor, the HLA-E 
      expression rates were 72.2 and 15.1 %, respectively (P < 0.05). Patients with 
      overexpression, low expression, and no expression of HLA-E exhibited disease-free 
      survival of 55.3, 72.9, and 72.1 %, respectively. Patients with HLA-E 
      overexpression exhibited the lowest long-term survival rate. No relationship was 
      observed between the type of HLA-E gene polymorphism and its expression level in 
      tumor tissues; moreover, no polymorphisms appeared to affect the long-term 
      survival of patients with colorectal cancer. The type of HLA-E polymorphism did 
      not have an impact on HLA-E expression in tumors or the prognosis in patients 
      with stage III colorectal cancer. However, the level of HLA-E expression in tumor 
      tissue strongly predicted long-term survival in these patients.
FAU - Zhen, Zi-Jun
AU  - Zhen ZJ
AD  - State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer 
      Center, 651 Dongfeng Road East, Guangzhou 510060, China. zhenzj@sysucc.org.cn
FAU - Ling, Jia-Yu
AU  - Ling JY
FAU - Cai, Yue
AU  - Cai Y
FAU - Luo, Wen-Biao
AU  - Luo WB
FAU - He, You-Jian
AU  - He YJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130203
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adenocarcinoma/*genetics/mortality/pathology
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Colorectal Neoplasms/*genetics/mortality/pathology
MH  - Disease-Free Survival
MH  - Genotype
MH  - Histocompatibility Antigens Class I/biosynthesis/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - *Polymorphism, Genetic
MH  - Prognosis
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - HLA-E Antigens
EDAT- 2013/02/05 06:00
MHDA- 2013/07/26 06:00
CRDT- 2013/02/05 06:00
PHST- 2013/01/10 00:00 [received]
PHST- 2013/01/22 00:00 [accepted]
PHST- 2013/02/05 06:00 [entrez]
PHST- 2013/02/05 06:00 [pubmed]
PHST- 2013/07/26 06:00 [medline]
AID - 10.1007/s12032-013-0482-2 [doi]
PST - ppublish
SO  - Med Oncol. 2013 Mar;30(1):482. doi: 10.1007/s12032-013-0482-2. Epub 2013 Feb 3.